Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: the high and the low of it

November 24, 2018 10:13am

Upside strength was dollar strong but downside weakness was cents weak

Volume says it all: 0 out of 27 upside had higher (than the 3 month average) volume and 2 out of 17 downside experienced greater volume (than the 3 month average).

There is no breadline for share pricing and fact based intelligence!

You could have been reading if you were a … SUBSCRIBER!

Some have stated, “I am the “weatherman” of the sector; forecasting and presenting conditions of the sector in a given period.”

RMi’s daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined and evaluated.

Daily analytics and metrics:

The Dow closed DOWN -178.74 or -0.73% to 24,285.95
The S&P closed DOWN -17.37 points or -0.66% to 2,632.56
The NASDAQ was DOWN -33.27 points or -0.48% to 6,938.98

From the pre-open newsletter: “a Black Friday for the sector with the NYSE and NASDAQ markets closing at 1 p.m. Is there a return policy for any of today’s low volume actions?”

The advance/decline line scenario of 45 covered companies:

The open was positive with an A/DL of 31/7 and 7 flats;
The close was positive with an A/DL of 2717 and 1 flat;

Pre-open indications:

I had stated, “I don’t expect MUCH from an abbreviated session and IF dips, slips and flips occur – they will be retraced by next week!”

Daily sector metrics:

… Greatest volume to the downside: HSGX, SGMO, MDXG, AST and XON

… Upside volume was weighted to: ADRO, VSTM, ONCE. IONS and CRSP

… Weakness ($) to the downside: RARE (-$0.35), BLCM (-$28), QURE (-$0.25), BCLI (-$0.12), and SLDB (-$0.16)

… Best moves ($) to the upside: BLUE (+$5.28), SAGE (+$3.35), RGNX (+$1.16), ALNY (+$0.66) and ONCE (+$0.62)

… The iShares NASDAQ Biotechnology (IBB) closed:

Friday was up +0.40% after NOT indicating in the pre-market;
Thursday was a holiday;
Wednesday was up +0.61% after indicating a POSITIVE +0.02% UPSIDE in the pre-market;
Tuesday was down -0.60% after indicating a NEGATIVE -0.47% DOWNSIDE in the pre-market;
Monday was down -2.14% after indicating a NEGATIVE -0.22% DOWNSIDE in the pre-market;
Last Friday was up +0.86% after indicating a POSITIVE +0.14% UPSIDE in the pre-market;

Henry’omics:

Sector equities jumped on extremely LOW volume on Friday as some of the most popular RegMed shares were up – BLUE (+$5.28), SAGE (+$3.35) and RGNX (+$1.16) as compared to those who fell – RARE (-$0.35), BLCM (-$0.28) and QURE (-$0.25) as volatility weighed on these equities.

For the week, the major indexes all dropped more than 3 percent. They also had their biggest loss for a Thanksgiving week since 2011.

Reiterating, “RegMed stocks have featured prominently in recent equity weakness; but I think it's important to discriminate within “our” universe. The weakness is being driven by the lack of clinical data to justify many shares pricing, but the outlook for the sector is less than hearty!”

The "bully pulpit":

Athersys (ATHX) closed up +$0.01 on Friday after Wednesday’s +$0.11 to $1.99 after Tuesday’s-$0.04 or -2.08% after Monday’s -$0.09 killing any of last week’s downs;

BioLife Solutions (BLFS) has gained again another +$0.30 after Tuesday’s +$0.42 and Monday’s drop of -$0.97 or -8.82% to $10.03;

Brainstorm Cell Therapy (BCLI) closed down -$0.17 after Wednesday’s +$0.08 after Tuesday’s +$0.02 after Monday’s +$0.02 to $3.17 after reporting a NEW (?) IND in a second indication - progressive multiple sclerosis (MS). BCLI plans to initiate a P2 study for progressive MS, expanding NurOwn beyond amyotrophic lateral sclerosis (ALS, pivotal P3 ongoing). WHY not get their first indication’s data – they’re always LOW on cash …?

Global Blood Therapeutics (GBT) closed up again +$0.55 after Wednesday’s +$0.98 to $33.99 after being maligned by this market post their “earnings” call closing FLAT ($33.01) on Tuesday after Monday’s flip -$3.30 or -9.09% to $33.01;

MiMedx (MDXG closed down again -$0.08 after Wednesday’s -$0.29 to $3.26 after Tuesday’s-$0.40 or -10.13% after Monday’s +$1.40 or +54.9% and its fellow past criminal Osiris (OSIR) closed up +$0.09 after Wednesday’s -$0.04 or -0.38% after Monday’s +$0.26 or +2.51 have taken-on a life of their own under the legal sword of legal Damocles. One question is Vericel (VCEL) closed up again +$0.15 after Wednesday’s +$0.04 after Tuesday’s +$0.02 after Monday’s -$0.36 or -2.12% being judged by the same ruler <they’re selling-into comparable markets). Let’s hope they’re NOT into STUFFING the channel!

Verastem (VSTM) barely bounced +$0.01 after Wednesday’s +$0.12 to $5.16 after taking a hits with Tuesday’s-$0.15 or -2.89% after Monday’s -$0.22 or 4.07% to $5.04. Oversold spread its share pricing wings – but, is there a management credibility issue?

Friday's night’s percentage (%) indicators:

Review the range of the 27 upside from +0.08% (FATE) to +5.17% (BSTG) while the 17 downside ranged from -09.8% (CUR) to -6.26% (BLCM) with a 1 flat close (RENE.L).

Volume stat:

0 out of 27 upside had higher (than the 3 month average) volume
2 out of 17 downside experienced greater volume (than the 3 month average).

November sessions:

Friday’s abbreviated session closed POSITIVE with 17 decliners, 27 advancers and 1 flat;

Thursday was a holiday

Wednesday closed POSITIVE with 8 decliners, 37 advancers and 0 flat;

Tuesday closed NEGATIVE with 29 decliners, 14 advancers and 2 flat;

Monday closed NEGATIVE with 37 decliners, 7 advancers and 1 flat;

Friday closed POSITIVE with 14 decliners, 28 advancers and 3 flat;

Thursday closed POSITIVE with 12 decliners, 33 advancers and 0 flat;

Wednesday closed NEGATIVE with 36 decliners, 7 advancers and 2 flats;

Tuesday closed NEUTRAL with 21 decliners, 21 advancers and 3 flats;

Monday closed NEGATIVE with 40 decliners, 4 advancers and 1 flat;

Friday closed NEGATIVE with 39 decliners, 6 advancers and 0 flat;

Thursday closed NEGATIVE with 26 decliners, 19 advancers and 1 flat;

Wednesday closed POSITIVE with 12 decliners, 32 advancers and 1 flat;

Tuesday closed NEGATIVE with 22 decliners, 21 advancers and 2 flats;

Monday closed NEGATIVE with 35 decliners, 7 advancers and 3 flats;

Friday closed POSITIVE with 20 decliners, 22 advancers and 3 flats;

Thursday (11/1) closed POSITIVE with 3 decliners, 42 advancers and 0 flat

In 23 sessions in October – there were 17 negative closes and 6 positive closes
In 19 sessions in September – there were 10 negative closes and 9 positive close;
In 21 August sessions – 6 had negative and 15 had positive closes

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

2 hours 55 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.